Lilly now stands alone with a viable oral GLP-1 candidate in late stage development
Availability: Out of stock Email when stock available Mix and Match Bulk Pricing Available (Kits Excluded) Buy 59 of any unit 5% off Buy 1019 of any unit 10% off Buy 20+ of any unit 15% off Discount reflected at checkout NOTICE: Our products are sold strictly for laboratory research and development purposes only
Rest in peace
Edt 122
During CEP, electronic excitation can be achieved either by photon absorption or by some chemical reaction such as charge-carrier recombination [113]
According to the data provided by the Synapse Database, As of August 26, 2024, there are 143 investigational drugs for the CB1 targets, including 133 indications, 120 R&D institutions involved, Nimacimab is a monoclonal antibody that targets the CB1 receptor and is being developed for therapeutic areas including Nervous System Diseases, Digestive System Disorders, Endocrinology and Metabolic Disease, and Urogenital Diseases
